Global Psychedelic Drugs Market

The Psychedelic Drugs Market size was valued at USD 4.86 Billion in 2024 and the total Psychedelic Drugs revenue is expected to grow at a CAGR of 15.10% from 2025 to 2032, reaching nearly USD 14.99 Billion.

Psychedelic Drugs Market Overview:

Psychedelics are a group of hallucinogenic substances whose main function is to cause non-ordinary states of consciousness (sometimes known as "trips") by blocking the serotonin 2A receptor. This results in unique psychological, visual, and auditory changes, as well as a significantly changed state of consciousness in many people.

To know about the Research Methodology :- Request Free Sample Report

Psychedelic Drugs Market Dynamics:

Sensory impressions, energy levels, cognitive functions, and spiritual experiences are all improved or altered by psychedelic drugs. The three forms of psychedelic drugs are dissociative drugs (such as phencyclidine), empathogens, and serotonergic drugs (such as lysergic acid diethylamide). These drugs are used to treat the major depressive disorder, treatment-resistant depression, panic disorder, post-traumatic stress disorder, and opiate addiction, among other conditions.

Due to the obvious advent of new psychedelic substances in recent years, the market for psychedelic drugs has seen substantial expansion. Furthermore, because psychedelic medications have repeatedly demonstrated their high rates of effectiveness in the treatment of nicotine addiction, alcohol addiction, and anxiety-related terminal illness, market growth is being driven by an increase in acceptance of the medications for treating depression.

Additionally, new product launches by the top market players for market expansion are further estimated to lift the growth of the psychedelic drug market. For instance- Janssen Pharmaceuticals, Inc. gained FDA approval for its Spravato nasal spray to treat suicidal persons in August 2021. According to the research, around 11–12% of Americans suffer from serious depressive disorder, which can lead to suicide. As a result of this approval, these patients received great therapy, and the corporation was able to collect more income.

Psychedelic Drugs Market Segment Analysis:

The Gamma-hydroxybutyric acid segment is anticipated to adhere to the growth of the Psychedelic Drugs Market.

In 2021, the gamma-hydroxybutyric acid segment will be the most popular, as Xyrem from Jazz Pharmaceutical is one of the oldest psychedelic medications on the market, with a large proportion of the market and belongs to the drug class. It's a Schedule III regulated substance, which means it needs to be prescribed and closely monitored by a physician. GHB in its prescription version is used to treat excessive daytime sleepiness. Gamma-hydroxybutyric acid also been used to treat alcoholism and drug withdrawal in few patients. GHB is used in the medical treatment of narcolepsy and, less commonly, alcoholism, however, its efficacy in comparison to other pharmacotherapies for alcoholism is yet unknown. It is occasionally used off-label to treat fibromyalgia. The active element of the pharmaceutical drug sodium oxybate is GHB (Xyrem). The United States Food and Drug Administration has approved sodium oxybate for the treatment of cataplexy and excessive daytime sleepiness (EDS) in people with narcolepsy.

The narcolepsy segment is supplementing the growth of the Psychedelic Drugs Market.

The narcolepsy section is expected to dominate in 2021, thanks to Jazz Pharmaceutical's Xyrem, which is used to treat the condition and is the market's largest stakeholder. Narcolepsy is a chronic sleep disorder characterised by daytime tiredness and sleep episodes. People with narcolepsy find it difficult to stay awake for long periods of time in any situation. Narcolepsy can create a slew of issues in your day-to-day existence. Despite the fact that narcolepsy is not a lethal disease, it can lead to accidents, injuries, and even life-threatening scenarios. People with narcolepsy may struggle to keep employment, do well in school, and maintain relationships due to attacks of severe daytime sleepiness.

Psychedelic Drugs Market Regional Insights:

North America is dominating the growth of the market in the forecast period owing to the increased prevalence of depression and mental diseases, regulatory reforms, advancements about psychedelics in the region. Further, shifting perspectives, less severe side effects associated with the medicaments, cost-effectiveness is projected to drive the growth of the market. the psychedelic pharmaceuticals industry is predicted to grow due to high demand in North America. However, the market faces some challenges, such as the uncertainty surrounding FDA approval, the early stage of the psychedelics industry's lifecycle, the stigma associated with psychedelic drug use, and so on.

The objective of the report is to present a comprehensive analysis of the Psychedelic Drugs Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Psychedelic Drugs Market dynamics, structure by analyzing the market segments and project the Psychedelic Drugs Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Psychedelic Drugs Market make the report investor’s guide.

Psychedelic Drugs Market Scope: Inquire before buying

Psychedelic Drugs Market, by Region

North America
1. US
2. Canada
3. Mexico
Europe
1. U.K
2. France
3. Germany
4. Italy
5. Spain
6. Sweden
7. CIS Countries
8. Rest of Europe
Asia Pacific
1. China
2. India
3. Japan
4. South Korea
5. Australia
6. ASEAN
7. Rest of Asia Pacific
The Middle East and Africa
1. South Africa
2. GCC Countries
3. Egypt
4. Nigeria
5. Rest of ME&A
South America
1. Brazil
2. Argentina
3. Rest of South America

Psychedelic Drugs Market, Key Players

1. Janssen Pharmaceuticals,
2. Hikma Pharmaceuticals PLC
3. COMPASS
4. Verrian
5. Pfizer Inc.
6. F. Hoffmann-La Roche Ltd.
7. Jazz Pharmaceuticals Inc.
8. PharmaTher Inc.
9. Avadel
10. Celon Pharma S.A.
11. NeuroRx, Inc.
12. usonainstitute.org
13. Celon Pharma S.A.
14. Red Light Holland
15. Neonmind Biosciences
16. Novamind
17. MindMed
18. Numinus
19. Entheon Biomedical

Frequently Asked Questions:

1. Which region has the largest share in Global Psychedelic Drugs Market?
Ans: North America region held the highest share in 2024.

2. What was the Global Psychedelic Drugs Market size in 2024?
Ans: The Global Psychedelic Drugs Market size was USD 4.86 Billion in 2024.

3. What is scope of the Global Psychedelic Drugs market report?
Ans: Global Psychedelic Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Psychedelic Drugs market?
Ans: The important key players in the Global Psychedelic Drugs Market are – , Janssen Pharmaceuticals,, Hikma Pharmaceuticals PLC, COMPASS, Verrian, Pfizer Inc., F. Hoffmann-La Roche Ltd., Jazz Pharmaceuticals Inc., PharmaTher Inc., Avadel, Celon Pharma S.A., NeuroRx, Inc., usonainstitute.org, Celon Pharma S.A., Red Light Holland, Neonmind Biosciences, Novamind, MindMed, Numinus, and Entheon Biomedical.

5. What is the study period of this market?
Ans: The Global Psychedelic Drugs Market is studied from 2024 to 2032.